E2F2

E2F2
Name	E2F transcription factor 2
Uniprot	P20371
Organism	Homo sapiens

E2F2 is a member of the E2F family of transcription factors implicated in control of cell cycle progression, DNA synthesis, and transcriptional regulation. It functions as a sequence-specific DNA-binding protein that modulates expression of genes required for S phase, and participates in complexes with tumor suppressors and cyclin-dependent regulators. E2F2 activity has been studied across human tissues, cancer cohorts, and model organisms including mouse, Drosophila, and zebrafish.

Function and Mechanism

E2F2 acts as a transcriptional regulator recognizing E2F-responsive promoters to control expression of genes such as Cyclin A, Cyclin E, Thymidine kinase 1, DNA polymerase alpha, and Cdc6. It participates in heteromeric complexes with members of the DP family and associates with pocket proteins including Retinoblastoma protein and p130 (protein), integrating signals from Cyclin-dependent kinase 2 and Cyclin-dependent kinase 4 pathways. Through interactions with factors implicated in transcriptional repression such as Histone deacetylase 1 and RBL2, E2F2 contributes to chromatin remodeling events mediated by complexes related to SWI/SNF. E2F2-dependent promoters are responsive to upstream signals from MAPK1, PI3K (phosphoinositide 3-kinase), and input from receptor pathways including Epidermal growth factor receptor, Insulin receptor, and Transforming growth factor beta signaling axes.

Gene and Protein Structure

The E2F2 gene is located in the human genome and encodes a protein containing a conserved DP dimerization domain and a winged-helix DNA-binding domain similar to other E2F family members. Structural studies reference motifs homologous to E2F1, E2F3, and E2F4 that mediate interactions with pocket proteins such as RB1 and regulatory kinases including Cyclin A2-CDK2. Post-translational modification sites include phosphorylation sites targeted by Cyclin-dependent kinase 2, acetylation marks catalyzed by P300, and ubiquitination signals recognized by E3 ligases like MDM2 and the SCF (Skp, Cullin, F-box) complex. Alternative promoter usage and transcript variants draw parallels with regulation observed in genes such as E2F1 and E2F3 across loci studied in consortia including Ensembl and GENCODE.

Regulation and Interactions

E2F2 is regulated by direct binding to tumor suppressors RB1 and CDKN1A (p21)-associated pathways, phosphorylation by complexes such as Cyclin A2–CDK2 and Cyclin D–CDK4/6, and dephosphorylation by phosphatases like PP2A. It interacts with transcriptional cofactors such as SP1, FOXM1, MYC, E2F6, DP1, and chromatin regulators including HDAC1 and CBP (CREB-binding protein). Ubiquitin-mediated turnover involves components of SKP2-containing complexes and proteasomal machinery studied alongside regulators like Cullin 1. MicroRNA-mediated control has been reported with miRNAs cataloged in datasets from miRBase and regulatory relationships comparable to those regulating MYC and TP53 transcripts. Cellular localization and activity cycles have been mapped in relation to mitogenic stimuli from EGF, PDGF, and stress pathways such as ATM/ATR signaling.

Role in Cell Cycle and Proliferation

E2F2 contributes to the G1/S transition by activating genes required for DNA replication and nucleotide biosynthesis, coordinating with regulators such as Cyclin E1, CDC25A, MCM2-7 complex, RPA1, and PCNA. In proliferative contexts, E2F2 acts alongside transcription factors E2F1 and E2F3 to drive S phase entry, while compensatory or repressive functions overlap with E2F4, E2F5, and E2F7 family members. Its activity influences cellular outcomes mediated by signaling from PI3K-AKT, MAPK, and checkpoint kinases including CHK1 and CHK2. In stem cell and progenitor populations, E2F2-regulated networks impact differentiation programs coordinated with factors like NOTCH1, SOX2, and OCT4.

Involvement in Disease and Cancer

Altered E2F2 expression or dysregulation has been observed in malignancies including breast cancer, lung cancer, colorectal cancer, hepatocellular carcinoma, and leukemia, with context-dependent roles as an oncogene or tumor suppressor comparable to patterns seen for E2F1 and MYC. Genetic and epigenetic changes affecting E2F2-linked pathways intersect with lesions in RB1, amplifications involving CCNE1, and alterations in TP53 signaling. Clinical studies and datasets from consortia such as The Cancer Genome Atlas and International Cancer Genome Consortium have profiled E2F2-associated signatures predictive of proliferation and prognosis alongside markers like Ki-67 and ERBB2. Beyond oncology, E2F2 contributes to pathologies involving aberrant proliferation such as atherosclerosis and regenerative defects observed in models of liver regeneration.

Experimental Studies and Model Organisms

Functional characterization of E2F2 has employed knockout and transgenic mice, RNA interference, CRISPR/Cas9 editing, and overexpression models paralleling approaches used for E2F1 and RB1 studies. Mouse models reveal developmental and hematopoietic phenotypes analyzed with techniques from flow cytometry, RNA-seq, and ChIP-seq comparable to genomic studies in ENCODE. Drosophila ortholog studies inform conserved mechanisms originally described in Drosophila melanogaster E2F pathways, and zebrafish models have been used to probe developmental roles analogous to investigations in Danio rerio embryogenesis. In vitro biochemical assays utilize recombinant domains studied with X-ray crystallography, NMR spectroscopy, and interaction screens similar to those applied to p53 and c-Myc complexes. Therapeutic research explores targeting E2F2-regulated circuits with CDK4/6 inhibitors approved for breast cancer and investigational agents profiled in trials cataloged by ClinicalTrials.gov.

Category:Transcription factors